Veronika Bachanova, MD
Hematology & Oncology · Minneapolis, MNNPI 1841327665
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,372 of the $33,384 with a category attached, or 88.0%. It is spread thinly across 16 manufacturers, the largest accounting for just 17.0%. Reporting peaked in 2022 at $9,010 and has fallen 65.4% since, to $3,120 in 2025. Among hematology & oncology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $927.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Gilead$5K
- ADC Therapeutics America, Inc.$4K
- Pfizer$3K
- Incyte Corporation$2K
- Rigel Pharmaceuticals, Inc.$2K
- plus $12K from 10 others
Across 126 payments — averaging $20,513 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$1.2M
- Bristol Myers Squibb$708K
- Gamida Cell Inc.$291K
- ADC Therapeutics America, Inc.$125K
- Novartis$90K
- E.r. Squibb & Sons, L.L.C.$80K
- plus $98K from 3 others
What the payments were for
- Consulting fees$29,37288%
- Speaking & faculty fees$2,2607%
- Travel & lodging$6182%
- Food & beverage$1,0943%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $5,670 |
| Gilead(2 entities) | 9 | $4,845 |
| ADC Therapeutics America, Inc. | 4 | $3,749 |
| Pfizer | 2 | $2,670 |
| Incyte Corporation | 1 | $2,460 |
| Rigel Pharmaceuticals, Inc. | 1 | $2,400 |
| Seagen Inc. | 1 | $2,260 |
| Beigene USA, Inc. | 1 | $2,250 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,095 |
| Gamida Cell Inc. | 1 | $2,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,856 |
| AbbVie | 2 | $1,013 |
| Autolus Inc | 1 | $36 |
| Genentech USA, Inc. | 1 | $36 |
| Genetix Biotherapeutics Inc | 1 | $30 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,384 in reported general payments places this provider in the 90th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 58 | $433,131 |
| ImbruvicaIbrutinib | 30 | $388,219 |
| CalquenceAcalabrutinib Maleate | 21 | $322,418 |
| BrukinsaZanubrutinib | 30 | $289,847 |
| RezurockBelumosudil Mesylate | 12 | $219,460 |
| EliquisApixaban | 16 | $13,588 |
| Acyclovir | 98 | $1,212 |
| Fluconazole | 15 | $707 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 63 | $602 |
| Gabapentin | 11 | $207 |
| Pantoprazole Sodium | 21 | $179 |
| Prednisone | 22 | $151 |
| Allopurinol | 20 | $107 |
| Prochlorperazine Maleate | 11 | $102 |
| Levofloxacin | 14 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $1,013 | $433,13158 claims |
| AstraZenecaCalquence | $5,670 | $322,41821 claims |
| Beigene USA, Inc.Brukinsa | $2,250 | $289,84730 claims |
| PfizerEliquis | $2,670 | $13,58816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 193 hematology & oncology providers in Minnesota.
Other hematology & oncology in Minneapolis
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Vicki MorrisonMinneapolis$354K
- Aimee MerinoMinneapolis$161K
- Daniel WeisdorfMinneapolis$64K
- Gautam JhaMinneapolis$55K
- Arpit RaoMinneapolis$46K
- Amit KulkarniMinneapolis$40K
- Gregory VercellottiMinneapolis$34K
- Marshall MazepaMinneapolis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.